Advertisement

Cannabinoide in der Palliativmedizin

  • Hans Georg Kress
  • Birgit Kraft
Chapter

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD (1997) Habitual smoking of marijuana and cocaine impairs alveolar macrophage function and cytokine production. J Resp Crit Care Med 156: 1606–1613Google Scholar
  2. 2.
    Beal JA (1994) Appetite effect of dronabinol. J Clin Oncol 12: 1524–1525PubMedGoogle Scholar
  3. 3.
    Campbell FA, Tramèr MR Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative and systematic review. BMJ 323: 13–16PubMedCrossRefGoogle Scholar
  4. 4.
    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Chistensen B (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20: 567–573PubMedCrossRefGoogle Scholar
  5. 5.
    Kalso E (2001) Cannabinoids for pain and nausea. BMJ 323: 2–3PubMedCrossRefGoogle Scholar
  6. 6.
    Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, DiMarzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534PubMedCrossRefGoogle Scholar
  7. 7.
    Mechoulam R, Hanu L (2001) The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6: 67–73PubMedGoogle Scholar
  8. 8.
    Radbruch L, Nauck F (2004) Cannabinoide in der Behandlung von übelkeit und Erbrechen. Schmerz 18: 306–310PubMedGoogle Scholar
  9. 9.
    Reynolds R (2002) Comparative efficacy of dronabinol and megestrol acetate. J Clin Oncol 20: 2912–2913PubMedGoogle Scholar
  10. 10.
    Smith PF (2002) Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 3: 859–864PubMedGoogle Scholar
  11. 11.
    Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? BMJ 329: 257–258CrossRefGoogle Scholar
  12. 12.
    Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71–81Google Scholar
  13. 13.
    Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the tratment of HIV wasting syndrome. Aids Res Human Retroviruses 13: 305–315CrossRefGoogle Scholar
  14. 14.
    Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323: 16–21PubMedCrossRefGoogle Scholar
  15. 15.
    Walker JM, Huang SM (2002) Cannabinoid analgesia. Phamacol Ther 95: 127–135CrossRefGoogle Scholar
  16. 16.
    Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2006

Authors and Affiliations

  • Hans Georg Kress
    • 1
  • Birgit Kraft
    • 2
  1. 1.Univ.-Klinik für Anästhesie und Allgemeine IntensivmedizinWien
  2. 2.Klinik für Anästhesie und Allgemeine IntensivmedizinWien

Personalised recommendations